AI tools are changing the way pharmaceutical companies and public health organizations think about finding treatments for rare diseases.
For example, Transcriptta Bio, A Silicon Valley-based pharmaceutical startup is using AI to match existing medicines with new use cases, according to a Bloomberg profile this week.
The company uses AI software to identify drugs that have the potential to reduce the impact of rare diseases. Rather than zeroing in on a single condition and seeing if the drug we're experimenting with affects the genes associated with that condition, Transcriptta starts with drugs that are already on the market and works backwards. .
Related: AI is changing how companies fill open roles and how candidates interact with their systems
The startup tests drugs identified as a match by its AI software to determine whether they have additional use cases and also impact genes associated with rare diseases. Masu.
Transcriptta's unusual approach may be more cost-effective. According to Bloomberg, the company claims it can screen for every known rare genetic disease for about $2 million, which is more than a drug company can pay to start researching a new drug for one disease. It's the amount.
The company has raised about $30 million to date.
“We have significantly improved our capital efficiency,” Chris Moxham, Transcriptta's chief executive officer and chief scientific officer, told the publication. “It's not just one disease at a time.”
Related: New AI chatbot revolutionizes business school curriculum and accreditation — what could this change?
Other startups, including Century Health, which secured $2 million in pre-seed funding last month, are also looking to leverage existing data about drugs into new real-time applications. In particular, Century Health is using its AI platform to commercialize breakthrough treatments for diseases such as Alzheimer's disease.
Startups aren't the only ones interested in AI applications for healthcare. His Nvidia, the AI chip giant, created an AI cloud service focused on AI-powered drug development, and last month released his 20 new AI tools for healthcare.
One standout tool is a bot called Hippocratic, which outperforms real nurses in every area, including how drugs affect the lab and the impact of test values compared to target ranges. Ta.
Related: Microsoft's new AI can make photos sing and talk
On the public health front, researchers at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), last week showed promise in predicting whether a patient will respond to a particular cancer. created an AI tool called PERCEPTION. More therapeutic than others.
In a study published Thursday in Nature Cancer, researchers wrote that PERCEPTION outperformed industry standards for predictors “in all clinical cohorts.”
